Aura Biosciences (AURA) Times Interest Earned (2020 - 2026)
Aura Biosciences' (AURA) quarterly Times Interest Earned came in at -$1.48 in Q1 2026, up 86.74% YoY from -$0.79 in Q1 2025, and up 95.42% on a QoQ basis from -$32.39 in Q4 2025.
Aura Biosciences (AURA) Times Interest Earned (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Times Interest Earned data on file, last reported at -$1.48 in Q1 2026.
- Quarterly Times Interest Earned rose 86.74% year-over-year to -$1.48 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.05 (up 87.26% YoY) and the FY2025 annual result came in at -$34.12, down 186.38% from the prior year.
- Times Interest Earned grew to -$1.48 in Q1 2026, from -$32.39 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.21 in Q1 2022 to a low of -$34.04 in Q4 2024.
- A 5-year average of -$8.78 and a median of -$1.79 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned surged 99.69% — and 2023, when it tumbled 636.27%.
- Tracing AURA's Times Interest Earned over 5 years: stood at -$22.93 in 2022, then plunged by 36.27% to -$31.25 in 2023, then dropped by 8.91% to -$34.04 in 2024, then climbed by 4.85% to -$32.39 in 2025, then jumped by 95.42% to -$1.48 in 2026.
- The last three Times Interest Earned figures came in at -$1.48 (Q1 2026), -$32.39 (Q4 2025), and -$3.75 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | -2.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.12 |
| Mar 31, 2026 | -1.48 |
| Dec 31, 2025 | -32.39 |
| Sep 30, 2025 | -3.75 |
| Jun 30, 2025 | -1.10 |
| Mar 31, 2025 | -11.18 |
| Dec 31, 2024 | -34.04 |
| Sep 30, 2024 | -2.11 |
| Jun 30, 2024 | -0.79 |
| Mar 31, 2024 | -2.90 |
| Dec 31, 2023 | -31.25 |
| Sep 30, 2023 | -1.79 |
| Jun 30, 2023 | -0.95 |
| Mar 31, 2023 | -1.53 |
| Dec 31, 2022 | -22.93 |
| Sep 30, 2022 | -0.37 |
| Jun 30, 2022 | -0.51 |
| Mar 31, 2022 | -0.21 |
| Dec 31, 2021 | -76.49 |
| Sep 30, 2021 | -0.63 |